We are pleased to announce that Veracyte’s Afirma Genomic Sequencing Classifier (GSC) now has expanded Medicare coverage for patients with “Bethesda V” thyroid nodules, or those that are suspicious for cancer. This pivotal milestone allows thousands of patients access to advanced technology to help guide their treatment based on the molecular characteristics of their nodules. John Leite, our Chief Commercial Officer, CLIA Business, shares his perspective on this important development for patients and personalized medicine. #Endocrinology #ThyroidCancer
Veracyte’s Afirma GSC test will now be covered by Medicare for patients with #ThyroidNodules that are suspicious for #ThyroidCancer. Here’s an article I wrote about why this is good news for patients and for personalized medicine more generally.
National Sales Account Executive at The Sourcing Group
3wWow! What a great accomplishment!